Welcome to our dedicated page for Apollomics news (Ticker: $APLM), a resource for investors and traders seeking the latest updates and insights on Apollomics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Apollomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Apollomics's position in the market.
Rhea-AI Summary
Apollomics Inc. announces the approval of Vebreltinib in China for the treatment of gliomas with MET fusion gene, making it the world's first c-Met inhibitor approved for CNS tumors. The approval is based on a Phase 2/3 trial. The collaboration with Avistone and the global SPARTA trial highlight the potential of Vebreltinib in treating solid tumors with c-Met alterations globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
-
Rhea-AI Summary
Apollomics Inc. presents preclinical data on vebreltinib showing efficacy in treating various tumor types with MET-driver alterations and overcoming resistance in EGFR-positive non-small cell lung cancer at the AACR Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
-
Rhea-AI Summary
Apollomics Inc. announced poster presentations on vebreltinib (APL-101) at the 2024 American Association for Cancer Research Annual Meeting. The presentations showcase the mechanism of action and anti-tumor activity of vebreltinib in diverse patient-derived tumor models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.95%
Tags
Rhea-AI Summary
Apollomics Inc. (APLM) reports continued clinical and regulatory progress for vebreltinib and completion of patient enrollment for uproleselan Phase 3 study in China. The company has $37.8 million in cash as of December 31, 2023, with a cash runway till Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.97%
Tags
-
News
Rhea-AI Summary
Apollomics Inc. will announce its full year 2023 financial results on March 28, 2024, followed by a conference call and webcast. The management team will discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
-
Rhea-AI Summary
Apollomics Inc. appoints Matthew Plunkett, Ph.D., as Chief Financial Officer to drive financial strategy and business development. Dr. Plunkett brings over 25 years of experience in the biopharmaceutical sector, enhancing Apollomics' growth and clinical trial progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
Rhea-AI Summary
Apollomics Inc. announced that its Chairman and CEO, Guo-Liang Yu, Ph.D., and President Sanjeev Redkar, Ph.D., will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024. The presentation will be accessible via live webcast and a replay will be available. Investors can arrange meetings with the company's management during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.43%
Tags
-
Rhea-AI Summary
Apollomics Inc. received a notification from Nasdaq stating that the company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share. The company has 180 days to regain compliance, with the possibility of an additional 180-day period if needed. Failure to regain compliance may lead to delisting from the Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Apollomics Inc. announced that its Chairman and CEO, Guo-Liang Yu, and President, Sanjeev Redkar, will participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference. The event will take place on January 18, 2024, at 11:00 a.m. ET. The live webcast will be accessible through B. Riley Securities, and an archived replay will be available on the Apollomics website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
Rhea-AI Summary
Apollomics Inc. (Nasdaq: APLM) completes enrollment in Phase 3 bridging study for uproleselan in relapsed or refractory acute myeloid leukemia patients in China
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
Apollomics Inc.
Nasdaq:APLM
APLM Rankings
APLM Stock Data
36.02M
52.14M
32.02%
10.46%
0.17%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
Foster City
About APLM
formerly known as cbt pharmaceuticals. at apollomics, we are a purpose driven company imagining a world without cancer. we let science drive our decision making to advance our programs. we believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve. apollomics is committed to the discovery and development of oncology combination therapies. we believe that combination regimens can achieve clinically meaningful, durable responses that will allow us to enhance outcomes for patients. we have in-licensed our assets from multiple partners and built strong collaborations to advance our pre-clinical and clinical development programs. when developing an asset, we begin with rigorous ind-enabling studies to establish sound mechanistic and scientific rationale and guide our development path. this path may be as a monotherapy, a combination therapy, or both. while our ultimate goal is to study each of our assets in combination with other agents, we h